Every material Form 8-K Gain Therapeutics, Inc. has filed with the SEC since September 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, and she will also serve as principal financial officer and principal accounting officer. The filing sets out her employment terms, including a $275,000 base salary, a target bonus of 35% of salary, and an option for 130,000 shares, which matter to shareholders because they define the compensation and severance commitments the company is taking on.
Appointment effective October 28, 2026; appointed on October 22, 2026
Annual base salary of $275,000 with an initial target bonus of 35% of base salary
Option to purchase up to 130,000 shares under the 2022 Equity Incentive Plan, vesting over four years
Severance of six months' base salary, or twelve months' base salary plus other benefits if terminated within twelve months after a change of control
Gain Therapeutics said a poster on long-term open-label extension data for rexaceract in Parkinson's disease will be presented at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, October 4-8, 2026. The company reported that MDS-UPDRS motor scores were stable over 12 months in 12 evaluable participants and that preliminary data show the drug is generally well tolerated, and it expects to submit a new Phase 2 protocol to the FDA in the coming weeks.
Poster to be presented at the Congress in Seoul, Korea, October 4-8, 2026
12 of 13 evaluable patients completed 12 months of dosing as of August 31, 2026; one more is scheduled to finish in November 2026
MDS-UPDRS motor scores stable over 12 months in the 12 evaluable participants, with no clinically meaningful progression
Company expects to start the Phase 2 trial in Parkinson's disease in the first quarter of 2027
Gain Therapeutics said its senior vice president of finance and principal financial officer, Gianluca Fuggetta, will resign effective September 30, 2026, to pursue other opportunities. The board appointed CEO Gene Mack as interim chief financial officer effective October 1, 2026, and the company is searching for a permanent replacement.
Gianluca Fuggetta gave notice on September 22, 2026; resignation effective September 30, 2026
Gene Mack, current President and CEO, appointed interim CFO effective October 1, 2026
Mack also assumes principal financial and principal accounting officer duties; his employment terms are unchanged
Company is conducting an ongoing search for a permanent principal financial officer
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Gain Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →